CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) said members of its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 8:15 a.m. PT in San Francisco.
A live webcast will be available on the company’s Events & Presentations page at https://crisprtx.gcs-web.com/events, and a replay will be archived on the company website for 14 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRSP gained 2.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $145M to the company's valuation, bringing the market cap to $5.78B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CRSP gained 2.54% while key biotech peers such as MRUS (-7.08%) and LEGN (-1.69%) mostly declined, suggesting a more company-specific move rather than a sector-wide pattern.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Clinical update | Positive | +3.7% | Zugo-cel efficacy and safety data across autoimmune and B-cell cancers. |
| Nov 10 | Earnings update | Negative | -1.0% | Q3 2025 net loss and high operating expenses despite ongoing programs. |
| Oct 10 | Preclinical data | Positive | -2.5% | Strong CTX460 AATD preclinical results using SyNTase platform. |
| Oct 02 | Partnership news | Positive | +10.1% | Monash Boston Hub launch highlighting collaborations including CRSP. |
| Oct 01 | Conference preview | Positive | +2.1% | Announcement of upcoming SyNTase AATD data presentation at ESGCT 2025. |
Recent news has often led to price moves aligned with the apparent sentiment, with one notable divergence on positive preclinical data.
Over the past months, CRISPR Therapeutics has reported several significant updates. On Dec 22, 2025, positive zugo-cel data in autoimmune disease and lymphoma coincided with a 3.67% gain. Q3 2025 financials on Nov 10, 2025 highlighted a net loss of $106.4M and the stock slipped 0.98%. Preclinical CTX460 AATD data on Oct 10, 2025 led to a 2.47% decline despite encouraging metrics. Collaborative news with Monash on Oct 2, 2025 and an ESGCT presentation on Oct 1, 2025 saw gains of 10.07% and 2.08%, respectively. Today’s conference appearance fits within this cadence of frequent scientific and strategic updates.
Market Pulse Summary
This announcement schedules CRISPR Therapeutics for a January 12, 2026 presentation at the high‑profile J.P. Morgan Healthcare Conference, providing a platform to update on its gene‑based medicine programs and strategy. In recent months the company reported notable zugo‑cel data, preclinical CTX460 results, and Q3 2025 financials, alongside active use of at‑the‑market equity financing. Investors may watch for new clinical metrics, pipeline timelines, and capital allocation details during the conference webcast.
AI-generated analysis. Not financial advice.
ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Founded over a decade ago, CRISPR Therapeutics is a leading gene editing company focused on developing transformative medicines for serious diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune, and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
CRISPR THERAPEUTICS® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When will CRISPR Therapeutics (CRSP) present at the J.P. Morgan Healthcare Conference?
How can investors watch the CRSP presentation at the January 12, 2026 conference?
How long will the CRISPR Therapeutics presentation replay be available after January 12, 2026?
Who from CRISPR Therapeutics will present at the January 12, 2026 event?
Will CRISPR Therapeutics (CRSP) disclose new financial guidance during the January 12, 2026 presentation?
Where is the J.P. Morgan Healthcare presentation taking place for CRSP on January 12, 2026?
